BillionToOne's Northstar Response Is a Stronger Predictor of Immunotherapy Outcomes Than Standard-of-Care Imaging for Cancer Patients in Peer

Synovus Financial Corp. (SNV) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2025Q3
while the forward P/E of 8.91 suggests potential value, the dramatic shift in credit provisioning from $3.2 million in 2025Q2 to $298.7 million in 2025Q3 warrants extreme caution regarding asset quality.
Synovus Financial Corp. (SNV) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Synovus Financial Corp. (SNV) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Jan 21, 2026 | $1.25vs $1.41-11.3% | —vs $615M |
| Q4 2025 | Oct 15, 2025 | $1.46vs $1.36+7.4% | $615Mvs $604M+1.8% |
| Q3 2025 | Jul 16, 2025 | $1.48vs $1.25+18.4% | $594Mvs $586M+1.3% |
| Q2 2025 | Apr 16, 2025 | $1.30vs $1.12+16.1% | $569Mvs $570M-0.2% |
Recent stock market news and headlines for Synovus Financial Corp. (SNV)
BillionToOne's Northstar Response Is a Stronger Predictor of Immunotherapy Outcomes Than Standard-of-Care Imaging for Cancer Patients in Peer

Key metrics vs top competitors for Synovus Financial Corp. (SNV)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $50.05 | $6.95B | 16.52 | 1.16% | 14.09% | 9.27% | 3.03% | |
| $144.41 | $10.99B | 15.82 | 68.52% | 19.79% | 11.67% | — | |
| $162.79 | $10.98B | 14.08 | 6.66% | 20.11% | 11.93% | — | |
| $58.74 | $8.56B | 14.40 | 2.23% | 26.11% | 14.78% | — | |
| $25.85 | $12.27B | 13.75 | 0.97% | 22.31% | 11.07% | — | |
| $17.89 | $36.27B | 12.87 | 4.38% | 16.63% | 8.81% | — |
Synovus Financial Corp. (SNV) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Synovus Financial Corp. (SNV) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jan 2, 2026·SEC
Dec 9, 2025·SEC
Dec 8, 2025·SEC
Feb 21, 2025·SEC
Get notified when SNV posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Synovus Financial Corp. (SNV) stock FAQ — growth, dividends, profitability & financials explained
Synovus Financial Corp. (SNV) grew revenue by 1.2% over the past year. Growth has been modest.
Yes, Synovus Financial Corp. (SNV) is profitable, generating $800.1M in net income for fiscal year 2024 (14.1% net margin).
Yes, Synovus Financial Corp. (SNV) pays a dividend with a yield of 3.03%. This makes it attractive for income-focused investors.
Synovus Financial Corp. (SNV) has a return on equity (ROE) of 9.3%. This is below average, suggesting room for improvement.
Synovus Financial Corp. (SNV) has a net interest margin (NIM) of 2.9%. NIM has been under pressure due to interest rate environment.
Synovus Financial Corp. (SNV) has an efficiency ratio of 36.2%. This is excellent, indicating strong cost control.